Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...
The research and investment firm believes Nvidia ( NASDAQ: NVDA) will slice into AMD's market share in these two areas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback